New Trends In Internal Medicine2009 - Prince of Songkla...

16

Transcript of New Trends In Internal Medicine2009 - Prince of Songkla...

Page 1: New Trends In Internal Medicine2009 - Prince of Songkla ...medinfo2.psu.ac.th/.../Abstract/New_Trends_In_Internal_Medicine2009.pdf · Sorafenib multikinase inhibitor Raf, VEGFR PDGPR
Page 2: New Trends In Internal Medicine2009 - Prince of Songkla ...medinfo2.psu.ac.th/.../Abstract/New_Trends_In_Internal_Medicine2009.pdf · Sorafenib multikinase inhibitor Raf, VEGFR PDGPR

Lung

Page 3: New Trends In Internal Medicine2009 - Prince of Songkla ...medinfo2.psu.ac.th/.../Abstract/New_Trends_In_Internal_Medicine2009.pdf · Sorafenib multikinase inhibitor Raf, VEGFR PDGPR
Page 4: New Trends In Internal Medicine2009 - Prince of Songkla ...medinfo2.psu.ac.th/.../Abstract/New_Trends_In_Internal_Medicine2009.pdf · Sorafenib multikinase inhibitor Raf, VEGFR PDGPR
Page 5: New Trends In Internal Medicine2009 - Prince of Songkla ...medinfo2.psu.ac.th/.../Abstract/New_Trends_In_Internal_Medicine2009.pdf · Sorafenib multikinase inhibitor Raf, VEGFR PDGPR
Page 6: New Trends In Internal Medicine2009 - Prince of Songkla ...medinfo2.psu.ac.th/.../Abstract/New_Trends_In_Internal_Medicine2009.pdf · Sorafenib multikinase inhibitor Raf, VEGFR PDGPR
Page 7: New Trends In Internal Medicine2009 - Prince of Songkla ...medinfo2.psu.ac.th/.../Abstract/New_Trends_In_Internal_Medicine2009.pdf · Sorafenib multikinase inhibitor Raf, VEGFR PDGPR
Page 8: New Trends In Internal Medicine2009 - Prince of Songkla ...medinfo2.psu.ac.th/.../Abstract/New_Trends_In_Internal_Medicine2009.pdf · Sorafenib multikinase inhibitor Raf, VEGFR PDGPR
Page 9: New Trends In Internal Medicine2009 - Prince of Songkla ...medinfo2.psu.ac.th/.../Abstract/New_Trends_In_Internal_Medicine2009.pdf · Sorafenib multikinase inhibitor Raf, VEGFR PDGPR
Page 10: New Trends In Internal Medicine2009 - Prince of Songkla ...medinfo2.psu.ac.th/.../Abstract/New_Trends_In_Internal_Medicine2009.pdf · Sorafenib multikinase inhibitor Raf, VEGFR PDGPR
Page 11: New Trends In Internal Medicine2009 - Prince of Songkla ...medinfo2.psu.ac.th/.../Abstract/New_Trends_In_Internal_Medicine2009.pdf · Sorafenib multikinase inhibitor Raf, VEGFR PDGPR
Page 12: New Trends In Internal Medicine2009 - Prince of Songkla ...medinfo2.psu.ac.th/.../Abstract/New_Trends_In_Internal_Medicine2009.pdf · Sorafenib multikinase inhibitor Raf, VEGFR PDGPR
Page 13: New Trends In Internal Medicine2009 - Prince of Songkla ...medinfo2.psu.ac.th/.../Abstract/New_Trends_In_Internal_Medicine2009.pdf · Sorafenib multikinase inhibitor Raf, VEGFR PDGPR
Page 14: New Trends In Internal Medicine2009 - Prince of Songkla ...medinfo2.psu.ac.th/.../Abstract/New_Trends_In_Internal_Medicine2009.pdf · Sorafenib multikinase inhibitor Raf, VEGFR PDGPR
Page 15: New Trends In Internal Medicine2009 - Prince of Songkla ...medinfo2.psu.ac.th/.../Abstract/New_Trends_In_Internal_Medicine2009.pdf · Sorafenib multikinase inhibitor Raf, VEGFR PDGPR
Page 16: New Trends In Internal Medicine2009 - Prince of Songkla ...medinfo2.psu.ac.th/.../Abstract/New_Trends_In_Internal_Medicine2009.pdf · Sorafenib multikinase inhibitor Raf, VEGFR PDGPR

Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target · anti–VEGF-A/VEGFR drugs (9); they also provided strong evidence that VEGF-A was necessary for the maintenance of the

Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target · anti–VEGF-A/VEGFR drugs (9); they also provided strong evidence that VEGF-A was necessary for the maintenance of the

ศูนย ผู ป วยปากแหว ง เพดานโหว และพิการแต กําเนิดบริเวณ ...medinfo2.psu.ac.th/cleftcenter/images/AnnualReport... ·

ศูนย ผู ป วยปากแหว ง เพดานโหว และพิการแต กําเนิดบริเวณ ...medinfo2.psu.ac.th/cleftcenter/images/AnnualReport... ·

Cancer Research Differential Effects of VEGFR-1 and VEGFR ... · VEGFR-1 in liver ECs. EC proliferation, migration, and capillary tube formation in vitro were suppressed more by VEGFR-2

Cancer Research Differential Effects of VEGFR-1 and VEGFR ... · VEGFR-1 in liver ECs. EC proliferation, migration, and capillary tube formation in vitro were suppressed more by VEGFR-2

Assessing the Activity of Cediranib, a VEGFR-2/3 …mct.aacrjournals.org/content/molcanther/10/5/861.full.pdf · Cediranib is a potent inhibitor of the VEGF receptor (VEGFR)-2 and

Assessing the Activity of Cediranib, a VEGFR-2/3 …mct.aacrjournals.org/content/molcanther/10/5/861.full.pdf · Cediranib is a potent inhibitor of the VEGF receptor (VEGFR)-2 and

Common Anorectal Disease - Prince of Songkla …medinfo2.psu.ac.th/surgery/Edu_be_document/document4/Common... · Common Anorectal Disease ... Endometritis Diverticular abscess ...

Common Anorectal Disease - Prince of Songkla …medinfo2.psu.ac.th/surgery/Edu_be_document/document4/Common... · Common Anorectal Disease ... Endometritis Diverticular abscess ...

Soluble VEGFR-2 Expression in Head and Neck Malignant Tumors

Soluble VEGFR-2 Expression in Head and Neck Malignant Tumors

Clinical Cancer Genotyping - CINVESTAVlabsergen.langebio.cinvestav.mx/bioinformatics/jacob/... · 2017. 10. 25. · EXEL-7647 EGFR, HER2, EphB4, VEGFR Inhibitor 2 EXEL-2880 MET, VEGFR-2

Clinical Cancer Genotyping - CINVESTAVlabsergen.langebio.cinvestav.mx/bioinformatics/jacob/... · 2017. 10. 25. · EXEL-7647 EGFR, HER2, EphB4, VEGFR Inhibitor 2 EXEL-2880 MET, VEGFR-2

nup yi - medinfo2.psu.ac.th

nup yi - medinfo2.psu.ac.th

VEGFR - file.medchemexpress.com

VEGFR - file.medchemexpress.com

Development/Plasticity/Repair VEGFR ... · PDF fileDevelopment/Plasticity/Repair VEGFR-1RegulatesAdultOlfactoryBulbNeurogenesisand MigrationofNeuralProgenitorsintheRostralMigratory

Development/Plasticity/Repair VEGFR ... · PDF fileDevelopment/Plasticity/Repair VEGFR-1RegulatesAdultOlfactoryBulbNeurogenesisand MigrationofNeuralProgenitorsintheRostralMigratory

VEGF-B inhibits apoptosis via VEGFR-1– mediated ...

VEGF-B inhibits apoptosis via VEGFR-1– mediated ...

Lymphatic Drainage Mice That Lack Dermal K14-VEGFR-3-Ig in ...

Lymphatic Drainage Mice That Lack Dermal K14-VEGFR-3-Ig in ...

Development/Plasticity/Repair VEGFR ...

Development/Plasticity/Repair VEGFR ...

in Wet AMD · 2014-09-11 · 1 3 6 7 4 ANGIOGENESIS VASCULOGENESIS VEGF-C VEGF-D VEGF VEGFR-3 (Flt-4) VEGFR-1 (Flt-1) VEGFR-2 (Flk-1) VEGF-A VEGF-B PIGF 1,2 Ras Raf MEK p38MAPK ERK

in Wet AMD · 2014-09-11 · 1 3 6 7 4 ANGIOGENESIS VASCULOGENESIS VEGF-C VEGF-D VEGF VEGFR-3 (Flt-4) VEGFR-1 (Flt-1) VEGFR-2 (Flk-1) VEGF-A VEGF-B PIGF 1,2 Ras Raf MEK p38MAPK ERK

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor … · RET point mut ations such as RET M918T are de tected in medul-lary thyroid cancers ( 2 ). RXDX-105 is an orally

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor … · RET point mut ations such as RET M918T are de tected in medul-lary thyroid cancers ( 2 ). RXDX-105 is an orally

VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced ...cancerres.aacrjournals.org/content/canres/73/2/539.full.pdf · VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory

VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced ...cancerres.aacrjournals.org/content/canres/73/2/539.full.pdf · VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory

HE Printed in U.S.A. Analysis of Biological Effects and ... · Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2) A REASSESSMENT USING NOVEL

HE Printed in U.S.A. Analysis of Biological Effects and ... · Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2) A REASSESSMENT USING NOVEL

Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 ...

Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 ...

Resistance to multikinase inhibitor actions mediated by ...

Resistance to multikinase inhibitor actions mediated by ...

The role of medical therapy in the management of desmoid tumor · Sunitinib: KIT, PDGFR , VEGFR and RET Sorafenib: KIT, PDGFR, VEGFR, RET and RAF. Sorafenib Gounder M.M. et al, ASCO

The role of medical therapy in the management of desmoid tumor · Sunitinib: KIT, PDGFR , VEGFR and RET Sorafenib: KIT, PDGFR, VEGFR, RET and RAF. Sorafenib Gounder M.M. et al, ASCO